Rani Therapeutics (NasdaqGM:RANI) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsStephen Jasper - Managing DirectorSvai Sanford - CFOTalat Imran - CEOConference Call ParticipantsBrandon Folkes - Senior Research AnalystMichael Okunewitch - Senior Research AnalystOperatorWelcome to the Rani fourth quarter and full year 2025 financial results and corporate update conference call. At this time, all participants are on a listen-only mode. Following management's prepared remarks, Rani will h ...

Rani Therapeutics (NasdaqGM:RANI) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsStephen Jasper - Managing DirectorSvai Sanford - CFOTalat Imran - CEOConference Call ParticipantsBrandon Folkes - Senior Research AnalystMichael Okunewitch - Senior Research AnalystOperatorWelcome to the Rani fourth quarter and full year 2025 financial results and corporate update conference call. At this time, all participants are on a listen-only mode. Following management's prepared remarks, Rani will h ...

Rani Therapeutics (NasdaqGM:RANI) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Speaker2Welcome to the Rani fourth quarter and full year 2025 financial results and corporate update conference call. At this time, all participants are on a listen-only mode. Following management's prepared remarks, Rani will hold a Q&A session. To ensure that you have ample time to address everyone's questioning during the Q&A session, we will ask you to limit yourself to one question and one follow-up. To ask a question at ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delawa ...

Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announ ...

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delive ...

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. Mr. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease. ...

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4: ...

Core Insights - Rani Therapeutics has promoted Alireza Javadi, Ph.D., to Chief Technical Officer, marking a significant leadership change as the company advances its pipeline and collaborations [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, aiming to replace subcutaneous injections or intravenous infusions with oral dosing through its proprietary RaniPill capsule technology [3] - The company has successfully conducted several preclinical and clinical studies to evaluate the safety, tolerability, and bioavailability of its RaniPill capsule technology [3] Leadership and Experience - Alireza Javadi previously served as Vice President of Technical Operations, overseeing Rani's R&D, manufacturing, and automation teams, and will now also be responsible for quality assurance in his new role [2] - His background includes five years as Director of Operations at Cretex Medical and various engineering and scientific roles, including Tooling and Engineering Manager at JunoPacific and Principal Scientist at the Wisconsin Institute for Discovery [2]

Core Insights - The latest data indicates significant increases in indicative borrow rates for various liquid option names, with Starfighters Space, Inc. (FJET) leading at 105.13% [1] Group 1: Borrow Rate Increases - Starfighters Space, Inc. (FJET) shows a borrow rate increase of 105.13%, up by 2.83 [1] - GraniteShares 1.5x Long COIN Daily ETF (CONL) has a borrow rate of 11.48%, increasing by 0.83 [1] - Icici Bank (IBN) reports a borrow rate of 1.10%, up by 0.80 [1] - EETH ETF (EETH) experiences a borrow rate of 19.93%, increasing by 0.59 [1] - Tradr 2X Long IREN Daily ETF (IREX) shows a borrow rate of 24.34%, up by 0.56 [1] - iShares Investment Grade Corporate Bond ETF (LQD) has a borrow rate of 3.00%, increasing by 0.55 [1] - Beyond Meat (BYND) reports a borrow rate of 12.97%, up by 0.49 [1] - Rani Therapeutics Holdings (RANI) shows a borrow rate of 18.04%, increasing by 0.44 [1] - Direxion Daily 20 plus Year Treasury Bear 3X Shares (TMV) has a borrow rate of 23.47%, up by 0.43 [1] - DeFi Development Corp (DFDV) reports a borrow rate of 10.50%, increasing by 0.39 [1]